dp13
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2017 (NCT03046589)
Timeline
Indications
Mechanism of action
- Cytochrome P450 19A1INHIBITOR
CYP19A1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dp13
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04007406 | Phase 2 | Sep 30, 2019 | Damian Pharma AG |
| NCT03046589 | Phase 1 | Mar 1, 2017 | Covance, Damian Pharma AG, University of Bern, University of Lausanne |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Damian Pharma AG | For profit | 2 | 2 | 2 | 2017 |
| Covance | For profit | 1 | 0 | 1 | 2017 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Lausanne | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1